Auriga Reiterates a 'Buy' on Medicis (MRX); Q1 Beat Underscores Execution
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $71.06 --0%
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Medicis (NYSE: MRX) price target of $47.00.
Analyst, Louise Chen, said, "Despite generic competition for the legacy strengths of Solodyn and the company's switch to alternate fulfillment channels for unprofitable Rxs (35% of retail Rxs unprofitable for Solodyn and Ziana), MRX was still able to report meaningful upside to consensus estimates and its own financial guidance for the quarter. Therefore, in our view this quarter underscores management's ability to execute through challenging situations. Furthermore, the integration of Graceway appears to be in-line with the company's guidance, and MRX continues to move forward with its pipeline of 18+ projects in development. Post the quarter, we still believe that the company's risk/reward profile is favorable. Its base business is at an upwards inflection point, and many potentially positive catalysts are not fully reflected in its stock price."
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $38.52 yesterday.
Analyst, Louise Chen, said, "Despite generic competition for the legacy strengths of Solodyn and the company's switch to alternate fulfillment channels for unprofitable Rxs (35% of retail Rxs unprofitable for Solodyn and Ziana), MRX was still able to report meaningful upside to consensus estimates and its own financial guidance for the quarter. Therefore, in our view this quarter underscores management's ability to execute through challenging situations. Furthermore, the integration of Graceway appears to be in-line with the company's guidance, and MRX continues to move forward with its pipeline of 18+ projects in development. Post the quarter, we still believe that the company's risk/reward profile is favorable. Its base business is at an upwards inflection point, and many potentially positive catalysts are not fully reflected in its stock price."
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $38.52 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marex Group PLC (MRX) PT Raised to $90 at Keefe, Bruyette & Woods
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Clear Street Downgrades Kinetik Holdings, Inc. (KNTK) to Hold Citing Valuation
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
